Author's response to reviews

Title: Fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: 12-month results of a phase 2 extension study

Authors:

Jun-ichi Kira (kira@neuro.med.kyushu-u.ac.jp)
Yasuto Itoyama (yitoyama@ncnp.go.jp)
Seiji Kikuchi (skikuti@hmc.hosp.go.jp)
Qi Hao (hao.mri.neuro@za.wakwak.com)
Takayoshi Kurosawa (takayoshi.kurosawa@novartis.com)
Kazuo Nagato (Nagato.Kazuo@mc.mt-pharma.co.jp)
Isao Tsumiyama (isao.tsumiyama@novartis.com)
Philipp von Rosenstiel (philipp.von_rosenstiel@novartis.com)
Lixin Zhang-Auberson (lixin.zhang_auberson@novartis.com)
Takahiko Saida (saida_takahiko@maia.eonet.ne.jp)

Version: 2 Date: 16 May 2013

Author's response to reviews: see over
Editor, *BMC Neurology*

16 May 2013

Dear Editor,

With regards to submission of our manuscript (ID 7201276049721539) entitled, *Fingolimod (FTY720) in Japanese patients with relapsing multiple sclerosis: 12-month results of a phase 2 extension study*, we understand that the journal requires the addition of a statement on ethics. To meet this request, the following text has been added to the methods section (page 4, ‘Study oversight and design’) of the manuscript:

‘The study (ClinicalTrials.gov number, NCT00670449) was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice [1] and the Declaration of Helsinki [2] and was overseen by an independent Data Safety Monitoring Board.’


On behalf of all authors, we thank you for the opportunity to revise our manuscript, and we hope this revision satisfies the journal’s ethical statement requirements. We look forward to hearing from you.

Best regards,

Jun-ichi Kira
Department of Neurology
Neurological Institute
Graduate School of Medical Sciences
Kyushu University
Fukuoka
Japan

Email: kira@neuro.med.kyushu-u.ac.jp Tel: 092-642-5337 Fax: 092-642-5352